Jommi, Claudio http://orcid.org/0000-0002-2862-2990
Galeone, Carlotta
Funding for this research was provided by:
MSD (MSD Oncology Policy Grant Program)
Article History
Accepted: 16 January 2023
First Online: 10 February 2023
Declarations
:
: This research has been funded by an unrestricted grant from MSD to Cergas Bocconi, through the MSD Oncology Policy Grant Program.
: Claudio Jommi has reported that Cergas Bocconi received grants from MSD to conduct this study. Claudio Jommi has served as an advisory board member and paid speaker for Amgen, Astrazeneca, BMS, CSL Behring, Gilead, Incyte, MSD, Roche, Sanofi, and Takeda outside the submitted work. Carlotta Galeone has served as an advisory board member for Incyte outside the submitted work.
: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
: Data used in this paper are available on AIFA’s website (ExternalRef removed). The database created on the grounds of the available data is available on request.
: Not applicable.
: Concept and design: CG, CJ. Acquisition of data: CG. Analysis and interpretation of data: CG, CJ. Drafting of the manuscript: CG, CJ. Obtaining funding: CJ. Administrative, technical, or logistic support: Not needed. Supervision: CJ.